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Edited by Jesus AvilaAbstract Previous studies have shown that acyl-coenzyme
A:cholesterol acyl transferase (ACAT), an enzyme that controls
cellular equilibrium between free cholesterol and cholesteryl es-
ters, modulates proteolytic processing of APP in cell-based
and animal models of Alzheimer’s disease. Here we report that
ACAT-1 RNAi reduced cellular ACAT-1 protein by 50%
and cholesteryl ester levels by 22% while causing a slight in-
crease in the free cholesterol content of ER membranes. This
correlated with reduced proteolytic processing of APP and
40% decrease in Ab secretion. These data show that even a mod-
est decrease in ACAT activity can have robust suppressive eﬀects
on Ab generation.
 2007 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Progressive accumulation of amyloid b-peptide (Ab) in se-
nile plaques in brain regions responsible for memory and cog-
nitive functions is a major pathological hallmark of
Alzheimer’s disease [1]. Ab is a 39–43-amino acid peptide gen-
erated from b-amyloid precursor protein (APP) by sequential
proteolytic cleavages mediated by b- and c-secretases. Alterna-
tively, APP can be processed by the non-amyloidogenic a-
secretase pathway, which cuts APP in the middle of the Ab
region [1]. Genetic, epidemiological and biochemical studies
have suggested that cholesterol is an important risk factor
for AD [2,3]. Statins, a highly successful class of drugs that in-
hibit HMG CoA reductase, have been shown to attenuate Ab
production in cell-based and animal models of AD and in
humans [4]. Although the beneﬁcial eﬀects of statins for AD
may be at least partially due to their pleiotropic actions, other
cholesterol-modifying strategies for suppression of Ab produc-
tion in Alzheimer’s disease have recently gained considerable
interest.
ACAT is an endoplasmic reticulum (ER)-resident enzyme
responsible for conversion of excess free cholesterol to cho-
lesteryl esters [5–7]. Of the two human ACAT isoforms (two*Corresponding author. Fax: +1 617 724 1823.
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doi:10.1016/j.febslet.2007.03.056diﬀerent genes in most mammals), ACAT-1 is ubiquitously ex-
pressed whereas ACAT-2 expression is restricted to the liver
and the intestine [6]. Inhibition of ACAT function in cells by
pharmacological means has been shown to eﬃciently suppress
Ab generation in vitro [8]. Importantly, a two-month treat-
ment with ACAT inhibitor CP-113,818 remarkably reduced
amyloid pathology and correlated with improved spatial learn-
ing in transgenic mice expressing human APP751 containing the
London (V717I) and Swedish (K670M/N671L) mutations [9].
To provide an important cell biological proof of principle
for ACAT-1 as a therapeutic target and as a modulator of
APP metabolism, we set up and characterized a cell-based
RNAi model for ACAT-1. Here, we show that reduction of
cellular ACAT-1 protein level to half by a single transfection
of ACAT-1 siRNA oligonucleotides reduces cellular choleste-
ryl ester levels while signiﬁcantly suppressing amyloidogenic
processing of APP and Ab production.2. Materials and methods
2.1. Cell culture and RNA interference
Human H4 neuroglioma cells (ATCC) were grown in Dulbecco’s
Modiﬁed Eagle Medium (DMEM) supplemented with 10% (v/v)
FBS (Atlanta Biologicals), 1% (v/v) L-glutamine–penicillin–streptomy-
cin solution (Sigma) at 37 C in a water–saturated air/5% CO2 atmo-
sphere. H4 cells were transfected with pcDNA3.1-APP751, selected
and maintained with G418 sulphate (Calbiochem). A clone
(H4APP751) with 5-fold overexpression of APP was used in this study.
For silencing ACAT-1 expression, cells were transfected with 1 or 3 lg
of a manufacturer-optimized mixture of human-speciﬁc ACAT-1 siR-
NAs (Santa Cruz Biotechnology) using Nucleofector technology
according to the manufacturer’s instructions (Amaxa). Control cells
were transfected with 3 lg of a mixture of mouse-speciﬁc ACAT-1 siR-
NAs (Santa Cruz Biotechnology). Culture media was changed once at
72 h post-transfection, and 24-h conditioned media was collected when
the cells were harvested at 96 h post-transfection.
2.2. Protein extraction and Western blotting
Cells were washed twice, scraped in ice-cold PBS and extracted on
ice for 30 min in a buﬀer containing 10 mM Tris–HCl, pH 6.8,
1 mM EDTA, 150 mM NaCl, 0.25% Nonidet P-40, 1% Triton X-100
and a protease inhibitor mixture (Roche Molecular Biochemicals). Cell
debris was removed by a spin at 16000 · g. The protein concentrations
were determined using the BCA protein assay kit (Pierce). For Western
blot analysis, 30 lg of total protein per lane was resolved in a 4–12%
gradient Bis–Tris gels (Novex) under reducing conditions. The ﬁlters
were probed with a C-terminal APP antibody (A8717; Sigma),
ACAT-1 (Santa Cruz) and GAPDH (Chemicon) antibodies. Calreticu-
lin (Calbiochem) and GM130 (BD Biosciences) antibodies were used to
identify ER and Golgi fractions, respectively. After incubation with
horseradish-conjugated secondary antibodies the signal was developed
using ECL Western Blotting detection reagent (Amersham). Western
blot images were quantitated using Quantity One software package
(Bio-Rad).blished by Elsevier B.V. All rights reserved.
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For the determination of cellular pools of free cholesterol (FC) and
cholesteryl esters (CE), cells were extracted in chloroform/methanol/
ddH2O (4:2:1; v/v/v). Chloroform phase was separated, mixed with
1:100 volume of polyoxyethylene 9-lauryl ether (‘polidocanol’; Sigma),
dried and resuspended in assay reaction buﬀer (100 mM potassium
phosphate, pH 7.4, 50 mM NaCl, 5 mM cholic acid, 0.1% Triton X-
100). Free cholesterol was measured enzymatically using Amplex
Red Cholesterol Assay kit (Molecular Probes/Invitrogen). To directly
measure cholesteryl esters in samples, free cholesterol was ﬁrst con-
verted to cholest-4-ene-3-one by cholesterol oxidase and the resulting
hydrogen peroxide decomposed by catalase after which the enzymatic
cholesterol assay was performed in the presence of cholesterol esterase
[10].2.4. Lipid droplet staining
Four days after transfection with 3.0 lg of ACAT-1 siRNA and
0.5 lg of pEGFP plasmid (Amaxa), cells were washed once with
PBS and ﬁxed with 3% paraformaldehyde in PBS for 20 min. Cells
were stained with HCS LipidTOX red neutral lipid stain and Hoe-
chst 33342 (Molecular Probes/Invitrogen) for 20 min according to
manufacturers instructions. Images were taken with Olympus DSU/
IX70 spinning disc confocal microscope. Control cells were treated
for 4 days with 10 lM CP-113,818 or vehicle (DMSO).2.5. Ab ELISA
For Ab determination, the conditioned media was cleared from
debris and secreted Ab40 and Ab42 were quantitated by standard
sandwich ELISA (Ab ELISA Core Facility, Center for Neurologi-
cal Diseases, Harvard Institutes of Medicine, Harvard Medical
School).2.6. Subcellular fractionation
ER membranes from transfected H4APP751 cells were prepared as de-
scribed previously [11].Fig. 1. Knockdown of ACAT-1 reduces cholesteryl ester levels. H4APP751 cell
increasing dose of human ACAT-1-speciﬁc siRNA oligonucleotides were an
levels. ACAT-1 expression determined by Western blot analysis (A) was q
cholesterol and cholesteryl ester levels are shown as the means ± S.D. of three
or 10 lM CP-113,818 or transfected with 0.5 lg GFP plasmid together with
oligonucleotides. After 96 h, cells were stained with HCS LipidTOX red ne
***P < 0.001. Bar = 10 lm.3. Results
3.1. Knockdown of ACAT-1 reduces cholesteryl ester levels in
cells
Human H4 neuroglioma cells overexpressing human APP751
(H4APP751) were transfected with an increasing dose of chemi-
cally synthesized ACAT-1 siRNA oligonucleotides (speciﬁc for
human ACAT-1). As a control, the cells were transfected with
siRNA oligonucleotides speciﬁc for mouse ACAT-1 which had
no detectable eﬀect on endogenous ACAT-1 protein levels in
H4APP751 cells. In previous studies, we have noted that for
ACAT inhibitors the maximal eﬃcacy in reducing cholesteryl
ester levels in cultured cells requires prolonged (up to 4 days)
incubation times [8]. Thus, cells were harvested 96 h after
transfection with ACAT-1 siRNA oligonucleotides for analy-
sis of ACAT-1 expression and cholesterol levels. At this point,
ACAT-1 protein levels were down by 42.7 ± 7.6% (P = 0.0052)
for 1.0 lg siRNA dose and 54.4 ± 11.0% (P = 0.0067) for
3.0 lg of siRNA dose as compared to the control siRNA-
transfected cells (Fig. 1A and B).
To determine how this reduction in ACAT-1 protein levels
aﬀect cellular cholesterol levels, both free cholesterol and cho-
lesteryl esters were determined from chloroform:methanol-ex-
tracted total lipids by enzymatic assay. We noted a
moderate, statistically insigniﬁcant rise [5.9% for 1.0 lg siRNA
(from 376.4 ± 18.5 to 398.4 ± 14.2 mg/g protein) and 6.2% for
3.0 lg siRNA (from 376.4 ± 18.5 to 399.7 ± 12.2 mg/g pro-
tein)] in free cholesterol level and highly signiﬁcant
14.6 ± 2.9% (from 289.8 ± 16.9 to 247.2 ± 10.8 mg/g protein;
P = 0.00013) and 21.6 ± 4.4% (from 289.8 ± 16.9 to 227.2 ±
17.0 mg/g protein; P = 0.00010) decreases in cholesteryl esters transfected with either mouse ACAT-1-speciﬁc (control siRNA) or an
alyzed 96 h after transfection for ACAT-1 expression and cholesterol
uantitated and normalized to GAPDH levels (B). (C) Cellular free
independent experiments. (D) H4APP751 cells were treated with DMSO
3.0 lg of either mouse ACAT-1 (control) or human ACAT-1 siRNA
utral lipid stain (lipid droplets) and Hoechst 33342 (nuclei). **P < 0.01,
1690 H.J. Huttunen et al. / FEBS Letters 581 (2007) 1688–1692levels in cells transfected with 1.0 lg and 3.0 lg ACAT-1 siR-
NA, respectively (Fig. 1C).
To verify that ACAT-1 RNAi aﬀects ACAT activity in the
transfected cells, we cotransfected GFP with ACAT-1 siRNA
oligonucletides and stained the cells with HCS LipidTOX red
neutral lipid dye and Hoechst 33342 nuclei dye to visualize
lipid droplets. As shown in Fig. 1D, treatment of cells with
ACAT inhibitor CP-113,818 abolished lipid droplet staining
from cells as compared to vehicle-treated (DMSO) cells. In
control cells transfected with mouse ACAT-1 siRNA and
GFP, lipid droplets are also clearly detectable (white arrow-
heads in Fig. 1D). Remarkably, in cells transfected with hu-
man ACAT-1 siRNA and GFP, the number and size of lipid
droplets is clearly reduced (black arrowheads) whereas the
non-transfected cells in the same culture display many lipid
droplets suggesting that in the cells transfected with ACAT-1
siRNA ACAT-1 activity is almost completely suppressed.
Altogether, these results show that in this RNAi model, a max-
imum of 54% reduction of ACAT-1 protein levels can be
achieved resulting in 22% decrease in cellular cholesteryl esters
and that transfection eﬃciency is the limiting factor for the eﬃ-
cacy of ACAT-1 RNAi in this cell-based model.Fig. 2. Decreased ACAT-1 expression levels correlate with reduced
proteolytic processing of APP. H4APP751 cells were transfected with
either control siRNA (mouse ACAT-1) or siRNA speciﬁc for human
ACAT-1 and analyzed 96 h later for ACAT-1 expression and APP
proteolytic fragments (A). The levels of the APP C-terminal fragments
(APP-C99 generated by b-secretase and APP-C83 produced by a-
secretase) were quantitated in four independent experiments (B). The
values were normalized to GAPDH and the immature form of APP
holoprotein (APP-im). *P < 0.05, **P < 0.01.
Fig. 3. Knockdown of ACAT-1 inhibits Ab generation. Conditioned
media collected from the cells examined in Fig. 2 was analyzed for
Abtotal and Ab42 by sandwich ELISA. The results shown represent the
means ± S.D. of four independent experiments. *P < 0.05, **P < 0.01.3.2. Knockdown of ACAT-1 expression reduces proteolytic
processing of APP and generation of Ab
Pharmacological ACAT inhibition as well as a selective dis-
ruption of ACAT-1 gene in AC29 cells has previously been
shown to aﬀect all three secretases (a, b and c) responsible
for proteolytic processing of APP [8]. To characterize the ef-
fects of ACAT-1 RNAi on APP metabolism, we ﬁrst analyzed
the levels of APP holoprotein as well as a-secretase (APP-C83)
and b-secretase (APP-C99) cleavage products of APP on Wes-
tern blots. As compared to the cells transfected with control
siRNA, the levels of amyloidogenic APP-C99 were down by
11.7 ± 2.7% (P = 0.0085) and 48.4 ± 5.2% (P = 0.0019) in cells
transfected with 1.0 lg and 3.0 lg of ACAT-1 siRNA, respec-
tively (Fig. 2A and B). The non-amyloidogenic APP-C83 level
was reduced by 27.4 ± 4.1% (P = 0.0036) in cells transfected
with 3.0 lg of ACAT-1 siRNA but was unaﬀected in cells
transfected with 1.0 lg of ACAT-1 siRNA (Fig. 2A and B).
APP holoprotein levels remained unaﬀected in all the samples.
Soluble Ab levels in the conditioned media from the siRNA-
transfected cells were analyzed by sandwich ELISA. As com-
pared to the cells transfected with control siRNA, conditioned
media from cells transfected with 1.0 lg of ACAT-1 siRNA
contained 18.5% (P = 0.0194) less total Ab and 21.8%
(P = 0.0316) less Ab42 (from 28.7 ± 3.7 to 23.4 ± 6.6 pmol/l/
mg protein and from 5.5 ± 1.4 to 4.3 ± 2.2 pmol/l/mg protein;
Fig. 3). Cells transfected with 3.0 lg of ACAT-1 siRNA pro-
duced 39.2% (P = 0.0027) less total Ab and 27.8%
(P = 0.0237) less Ab42 as compared to the control siRNA-
transfected cells (from 28.7 ± 3.7 to 17.5 ± 4.6 pmol/l/mg pro-
tein and from 5.5 ± 1.4 to 4.0 ± 1.1 pmol/l/mg protein;
Fig. 3). These results show that by reducing cellular ACAT-1
protein levels by 50%, a signiﬁcant suppression of amyloido-
genic APP processing can be achieved.3.3. ACAT-1 RNAi increases unesteriﬁed cholesterol content in
ER membranes
Our previous studies have indicated that lack of ACAT-1
activity in cells results in transient increases in free cholesterollevels in the ER [8]. As it is likely that this is mechanistically
relevant, we tested whether ACAT-1 RNAi had a similar eﬀect
on ER free cholesterol as treatment with a well-characterized
Fig. 4. ACAT-1 inhibitor and RNAi increases cholesterol content of ER membranes. Microsomes from H4APP751 cells were isolated by
centrifugation at 100000 · g, rehomogenized and separated in Optiprep gradients. (A) Fractions were analyzed for ER (calreticulin) and Golgi
markers (GM130), and for ACAT-1 and APP. (B) Cells were treated with 10 lM CP-113818 or transfected with 3 lg of ACAT-1 or control siRNA.
After 96 h, ER fractions were prepared and membrane cholesterol content in fractions containing ACAT-1 and calreticulin was assayed and
normalized to protein levels. *P < 0.05, **P < 0.01.
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3.0 lg of control or ACAT-1 siRNA oligonucleotides or trea-
ted with 10 lM CP-113,818 for 4 days. Microsomes were har-
vested and subjected to further fractionation in Optiprep
gradients. ACAT-1 and calreticulin-containing ER fractions
(as indicated in Fig. 4A) were assayed for free cholesterol.
Treatment with CP-113818 increased ER free cholesterol con-
tent by 47.6% (from 14.0 ± 3.5 to 20.7 ± 3.8 mg/g protein;
P = 0.0013) whereas ACAT-1 RNAi caused a 16.3% increase
(from 13.1 ± 1.9 to 15.3 ± 2.1 mg/g protein; P = 0.0248)
(Fig. 4B).4. Discussion
Cholesterol homeostasis has proven to be intimately linked
to various aspects of Ab biology [2,3]. In addition to statins,
ACAT inhibitors are promising therapeutic strategies for Alz-
heimer’s disease since both reduce amyloid plaque density in
animal models of the disease. It appears that the balance be-
tween amyloidogenic and non-amyloidogenic APP processing
is especially sensitive to changes in intracellular cholesterol dis-
tribution [8,9]. As ACAT is a key regulator of the equilibrium
between free cholesterol and cholesteryl ester pools, it is not
surprising that inhibition of ACAT suppresses proteolytic pro-
cessing of APP. In this study, we investigated whether a knock-
down of ACAT-1 expression by RNAi in cells aﬀects
proteolytic processing of APP and production of Ab. To detect
secreted Ab species in the culture medium we used a model
overexpressing human APP751. It should be noted that we have
detected similar suppressive eﬀects of ACAT-1 RNAi on the
proteolytic processing of endogenous APP in H4 naive cells
(data not shown). To control the speciﬁcity of the RNAi we
transfected a mixture of three siRNA oligonucleotides speciﬁc
for mouse ACAT-1 to human cells. Importantly, even in the
high 3 lg dose the control siRNA did not display any eﬀects
on the key parameters of this study, ACAT-1 expression, FC
and CE levels and APP/Ab levels. As we routinely perform
4-day treatments in cell-based ACAT-inhibitor studies, this
study was designed to be a 4-day study for comparability.
Importantly, RNAi-induced decrease in ACAT-1 expression
to roughly half of the control cell levels resulted in a signiﬁcant
suppression of Ab production (40%) despite the rather mod-
est 22% decrease in cholesteryl ester levels. Both Ab40 andAb42 were aﬀected more or less equally. These results are com-
parable to the previously published results that used ACAT-1
inhibitors [8]. Interestingly, ACAT-1 RNAi caused a similar
although smaller increase in the free cholesterol content of
ER membranes as pharmacological ACAT inhibition. This
may have important mechanistic implications and require fur-
ther studies.
As has been previously shown for pharmacological ACAT
inhibition [8], the results presented here suggest that ACAT-
1 RNAi aﬀects all of the three a-, b- and c-secretases as not
only Ab and APP-C99 but also APP-C83 levels were decreased
by ACAT-1 RNAi. Although the mechanistic details on how
ACAT inhibition modulates APP processing require further
studies, it seems that pharmacological ACAT inhibition and
ACAT-1 RNAi aﬀect the same or similar pathways in the early
secretory pathway that are important for APP metabolism.
Recently, the speciﬁcity of certain ACAT inhibitors has been
questioned [12]. Thus, this study provides an important, non-
pharmacological proof-of-principle conﬁrming that reduction
of cellular ACAT activity is a viable and speciﬁc approach
for modulating Ab generation.
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